Please login to the form below

Not currently logged in
Email:
Password:

UCB’s Mark Bodmer elected to BIA board

Will hold the position for a three-year fixed term

ucb mark bodmerUCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).

Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.

As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.

Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.

His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.

10th November 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics